

OHMR Research Ethics and Governance Metrics Program



Metrics Activity Report for NSW PHOs

Reporting Period: Quarter 1 2025
01/01/2025 – 31/03/2025

NSW Office for Health and Medical Research

Executive Summary

This report includes strategic and site level performance and compliance metrics that are collected by the Office for Health and Medical Research (OHMR) from NSW Public Health Organisations (PHOs) on studies authorised during the reporting period. The performance of NSW PHOs on health and medical research are reported four times a year, each covering a 3-month period.

Overall Performance Environment

REGIS is the online platform used to manage ethics and governance applications for all NSW Public Health Organisations. OHMR has undertaken data validation activities with LHD Research Office staff to accurately represent research ethics and governance performance on this platform. These rolling validation activities may result in data reported here to differ from previous reports.

Update to Metrics Program

As reported previously, OHMR implemented the following changes to the Research Key Performance Indicators (KPIs) for inclusion in the Chief Executives' Services Agreement:

- Number of Greater than Low Risk projects (GLR) processed within application total time
 - 90 days for ethics, 60 days for governance
 - Threshold changes
 - >75% = Performing
 - 55%-75% = Underperforming
 - <55% = Not performing



Ethics Review Timelines of Human Research in NSW PHOs

KPI21-03: Ethics Application Approvals - By the Human Research Ethics Committee (HREC) within 90 calendar days

NSW State Benchmark: The benchmark for the 2021/22 financial year onwards is for reviewing human research studies by NSW PHO HRECs within 90 calendar days

Definition:

The proportion of Ethics applications (excluding LNR) approved by the HREC within 90 calendar days, approved within the reporting period.

Context:

The measure will no longer account for clock stops in accordance with the NHMRC Certification Handbook. Instead, the end-to-end time will be measured. Where a valid application is received, the clock starts on the submission closing date for the HREC meeting at which an application will be reviewed. The clock is stopped when the HREC formally notifies the applicant of the final decision.

Desired Outcome:

Ensuring timely processing of ethics approvals for research and clinical trials supports better health outcomes for the people of NSW and maintaining competitiveness through access to the latest treatments from clinical trials.

Selection Criteria Summary:

Scope	Human Research Ethics Applications
Frequency	Quarterly
Inclusions	- Study Type = All - Application Type = Greater than low risk - Approval Type = Approved/ Approved with conditions within the reporting period
Exclusions	- Application Type = Low and negligible risk - Approval Type = Not within the reporting period - Migrated studies
Total	Total time is defined as the measurement of the total, unadjusted time from the Submission Closing Date of the first meeting the application is assigned to, to when the final decision notification email is sent.

Summary for Metric 3







Ethics review performance of NSW HRECs according to the < **90-day benchmark** for studies approved during the reporting period (**Quarter 1 2025**) are shown in **Table 1**.

During the reporting period, 188 studies (greater than low risk pathway) were approved by a NSW Health HREC with an average review time (total time) of 54 days. Of these 188 studies, 64 (34%) were classified as clinical trials (**Table 2**).

Further breakdown of clinical trial approvals by sponsor type is provided in **Table 3** (by NSW PHOs) and **Table 4** (by quarter). Historical performance of NSW PHOs against the old and new benchmarks for the review and approval of human research ethics applications is presented in **Table 5**.


Trends of performance for NSW PHO's **Ethics Approvals within 90 days**

— LHD — NSW




— LHD — NSW


SCHN



SESLHD




SLHD-CCD




SLHD-RPA



SVHN




SWSLHD





WNSWLHD



WSLHD









Overall breakdown and breakdown by NSW LHDs by **Sponsor Types** of Ethics Approvals for reporting period Q1 2025.









Trend of **Average Research Office Days** and **Average Researcher Days** for all GLR Ethics Approval over the reporting period Q4 2022- Q1 2025





Research Office Researcher



Research Office Researcher



Research Office Researcher





Site-specific Assessment (SSA) Authorisation Timelines of Human Research Projects in NSW PHOs

KPI21-04: Research Governance Application Authorisations – SSA Authorisations within 60 calendar days

NSW State Benchmark: The benchmark for the 2021/22 financial year onwards for authorisation of SSA applications is 60 calendar days

Definition:

The proportion of site-specific assessment (SSA) applications (excluding lower to negligible risk) authorised by the Research Governance Office (RGO) within 60 calendar days, authorised within the reporting period.

Context:

The measure will no longer account for clock stops in accordance with the National Health and Medical Research Council Certification. Handbook. Instead, the end-to-end time will be measured. The SSA application received date is the date the RGO or designee receives an SSA application from a researcher regardless of whether it is complete and/or deemed valid. The clock is stopped when the final SSA decision letter is provided to the site principal investigator.

Desired Outcome:

Ensuring timely processing of site approvals for research and clinical trials supports better health outcomes for the people of NSW and maintaining competitiveness through access to the latest treatments from clinical trials.

Selection Criteria Summary:

Scope

Site-specific assessment (SSA) applications

Frequency

Quarterly

Inclusions

- Study Type = All
- Application Type = Greater than low risk
- Approval Type = “Authorised” or “authorised with conditions” within the reporting period

Exclusions

- Application Type = Low and negligible risk
- Migrated studies

Total Time:

Total time is the measurement of the total, unadjusted time from the Submission Date to when the final decision notification email is sent granting approval.

Summary:

SSA review performance of NSW PHOs according to the **<60-day benchmark** for studies authorised during the reporting period (**Quarter 1 2025**) are shown in **Table 6**. During the reporting period,









366 studies (greater than low risk pathway) were authorised in NSW PHOs with an average review time (total time) of **43** days.

Of these **366** studies, **179** were classified as clinical trials (**Table 7**).









Further breakdown of clinical trial SSA authorisations by sponsor type is provided in **Table 8** (by NSW PHOs) and **Table 9** (by quarter). Historical performance of NSW PHOs against the old and new benchmarks for the review and authorisation of governance applications is presented in **Table 10**.

Trend of **Average Research Office days** and **Average Researcher days** for all GLR SSAs Authorisations by LHD
over reporting period Q4 2022 - Q1 2025







— Research Office — Researcher




Research Office Researcher




Research Office Researcher



Overall breakdown and breakdown by LHDs of SSA Authorisations by **Sponsor Types** for reporting period Q1 2025.




Breakdown of **Sponsor Type** by LHDs for SSA Authorisations in Q1 2025.











Trends of performance for NSW PHO's SSA Authorisations within 60 days

— LHD — NSW




LHD NSW




— LHD — NSW


SLHD-RPA




SNSWLHD




SVHN




SWSLHD




WNSWLHD




WSLHD




Average total time (days) for Clinical Trials Authorisation by Sponsor Type trends between Q2 2022 and Q1 2025




Average research office time (DAYS) for Clinical Trial Authorisation by Sponsor type trends between Q2 2022 and Q1 2025




Breakdown of **Sponsor Type** of all GLR **SSA Authorisations** by Site




Breakdown of **Sponsor Type** of all GLR **SSA Authorisations** by Site



Breakdown of **Study Types** for all GLR **SSA Authorisations** by Site



Breakdown of **Study Types** for all GLR **SSA Authorisations** by Site



OHMR Research Ethics
and Governance Metrics
Program
Appendix 1



Metrics Activity Report for NSW PHOs

Reporting Period: Quarter 1 2025
01/01/2025 – 31/03/2025

NSW Office for Health and Medical Research



Table 1. The **90 calendar days benchmark** for approval of human research ethics applications (**greater than low risk**) during the reporting period.

NSW PHOs	Ethics Approval (Q1 2025)					
	All greater than low risk applications					
	Total Number of Applications	Total Time 90 Day Benchmark			Total Time Breakdown (calendar days)	
		Count < 90 Day Benchmark	% < 90 Day Total Time Benchmark	Average Total Time (Days)	Average Research Office Time	Average Researcher Time
BLLBRRY	23	19	83%	48	25	23
CINSW	13	10	77%	103	53	50
HNELHD	14	14	100%	26	15	11
ISLHD	0	0	-	-	-	-
JHFMHN	2	1	50%	86	80	6
NBMLHD	3	2	67%	79	64	15
NNSWLHD	0	0	-	-	-	-
NSLHD	32	31	97%	49	34	15
SCHN	8	5	63%	86	53	33
SESLHD	13	11	85%	67	44	23
SLHD-CCD	6	6	100%	58	28	30
SLHD-RPA	28	20	71%	74	31	42
SVHN	15	13	87%	62	26	36
SWSLHD	15	13	87%	71	45	26
WNSWLHD	6	4	67%	71	36	35
WSLHD	10	7	70%	77	39	38
TOTAL	188	156	83%	54	33	20

Table 2. The 90 calendar days benchmark for the approval of clinical trials (greater than low risk) during the reporting period.

NSW PHOs	Ethics Approval (Q1 2025)					
	Clinical Trials					
	Total Number of Applications	Total Time 90 Day Benchmark			Total Time Breakdown (calendar days)	
		Count < 90 Day Benchmark	% < 90 Day Total Time Benchmark	Average Total Time (Days)	Average Research Office Time	Average Researcher Time
BLLBRRY	23	19	83%	48	25	23
CINSW	0	0	-	-	-	-
HNELHD	5	5	100%	31	17	13
ISLHD	0	0	-	-	-	-
JHFMHN	0	0	-	-	-	-
NBMLHD	3	2	67%	79	64	15
NNSWLHD	0	0	-	-	-	-
NSLHD	7	6	86%	63	39	24
SCHN	1	1	100%	85	75	10
SESLHD	4	3	75%	83	51	32
SLHD-CCD	2	2	100%	75	32	43
SLHD-RPA	11	4	36%	105	48	57
SVHN	4	4	100%	38	16	22
SWSLHD	1	1	100%	89	55	34
WNSWLHD	0	0	-	-	-	-
WSLHD	6	5	83%	83	40	42
TOTAL	64	47	73%	66	35	30

Table 3. Breakdown of NSW PHO performances in **clinical trial approvals** (greater than low risk) during the reporting period **by sponsor type**

	Collaborative group			Commercial entity			Investigator-initiated		
NSW PHOs	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)
BLLBRRY	0	-	-	22	19	39	1	162	247
CINSW	0	-	-	0	-	-	0	-	-
HNELHD	0	-	-	3	20	41	2	14	16
ISLHD	0	-	-	0	-	-	0	-	-
JHFMHN	0	-	-	0	-	-	0	-	-
NBMLHD	1	98	121	1	39	59	1	55	58
NNSWLHD	0	-	-	0	-	-	0	-	-
NSLHD	0	-	-	3	29	52	4	46	71
SCHN	0	-	-	0	-	-	1	75	85
SESLHD	0	-	-	2	75	115	2	27	52
SLHD-CCD	0	-	-	0	-	-	2	32	75
SLHD-RPA	6	49	102	2	37	77	3	55	131
SVHN	1	19	65	2	10	19	1	25	51
SWSLHD	1	55	89	0	-	-	0	-	-
WNSWLHD	0	-	-	0	-	-	0	-	-
WSLHD	0	-	-	3	40	70	3	40	95
Grand Total	9	52	99	38	26	48	20	47	84

Table 4. Quarterly **clinical trial approvals** (greater than low risk) in the last 3 reporting period (between 01/07/2024 and 31/03/2025), **by sponsor type**

	Q3 2024			Q4 2024			Q1 2025		
Sponsor Type	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)
Collaborative Group	10	36	70	11	42	75	9	52	99
Commercial Entity	61	28	54	58	28	48	38	26	48
Investigator Initiated	29	37	66	30	40	64	20	47	84
Total	100	34	63	99	37	62	67	42	77

Table 5. Historical performance of NSW PHOs against **the old and new benchmarks** for the review and approval of human research ethics applications (greater than low risk) in the last 3 reporting period (between 01/07/2024 and 31/03/2025).

NSW PHOs		Q3 2024							Q4 2024							Q1 2025						
		Total Number of Applications	45 Day Benchmark (with clock)			90 Day Benchmark (without clock)			Total Number of Applications	45 Day Benchmark (with clock)			90 Day Benchmark (without clock)			Total Number of Applications	45 Day Benchmark (with clock)			90 Day Benchmark (without clock)		
			Count 45 Day Benchmark	% 45 Day Benchmark	Average Research Office Time (Days)	Count 90 Day Benchmark	% 90 Day Total Time Benchmark	Average Total Time (Days)		Count 45 Day Benchmark	% 45 Day Benchmark	Average Research Office Time (Days)	Count 90 Day Benchmark	% 90 Day Total Time Benchmark	Average Total Time (Days)		Count 45 Day Benchmark	% 45 Day Benchmark	Average Research Office Time (Days)	Count 90 Day Benchmark	% 90 Day Total Time Benchmark	Average Total Time (Days)
BLLBRRY	39	34	87%	26	36	92%	50	38	34	89%	16	35	92%	40	23	19	83%	23	19	83%	48	
CINSW	7	5	71%	31	6	86%	67	14	13	93%	16	12	86%	63	13	10	77%	50	10	77%	103	
HNELHD	21	21	100%	8	21	100%	27	28	28	100%	4	28	100%	21	14	14	100%	11	14	100%	26	
ISLHD	0	0	-	-	0	-	-	0	0	-	-	0	-	-	0	0	-	-	0	-	-	
JHFMHN	2	2	100%	26	1	50%	89	2	1	50%	31	1	50%	117	2	2	100%	6	1	50%	86	
NBMLHD	4	4	100%	19	4	100%	53	1	0	0%	55	1	100%	87	3	3	100%	15	2	67%	79	
NNSWLHD	1	1	100%	19	0	0%	92	2	1	50%	38	1	50%	97	0	0	-	-	0	-	-	
NSLHD	36	33	92%	14	36	100%	27	25	25	100%	11	25	100%	33	32	31	97%	15	31	97%	49	
SCHN	15	14	93%	22	14	93%	63	12	11	92%	31	10	83%	71	8	5	63%	33	5	63%	86	
SESLHD	23	19	83%	25	18	78%	80	24	20	83%	24	18	75%	80	13	10	77%	23	11	85%	67	
SLHD-CCD	9	8	89%	22	9	100%	44	4	2	50%	28	4	100%	54	6	5	83%	30	6	100%	58	
SLHD-RPA	38	33	87%	26	36	95%	50	51	48	94%	20	48	94%	46	28	18	64%	42	20	71%	74	
SVHN	21	15	71%	34	17	81%	62	13	9	69%	42	10	77%	76	15	9	60%	36	13	87%	62	
SWSLHD	24	20	83%	22	18	75%	65	24	20	83%	23	14	58%	82	15	12	80%	26	13	87%	71	
WNSWLHD	3	2	67%	28	2	67%	90	3	3	100%	12	3	100%	47	6	4	67%	35	4	67%	71	
WSLHD	25	16	64%	42	18	72%	80	23	18	78%	39	21	91%	75	10	5	50%	38	7	70%	77	
TOTAL	268	227	85%	21	236	80%	54	264	233	88%	21	231	80%	54	188	147	78%	21	156	80%	54	

Table 6: The 60 calendar days benchmark for authorisation of governance applications (greater than low risk) during the reporting period.

NSW PHOs	SSA Approvals (Q1 2025)							
	All greater than low risk applications							
		60 Day Benchmark (without clock)			Total Time Breakdown (calendar days)			
	Total Number of Applications	Count of < 60 Day Benchmark	% < 60 Day Total Time Benchmark	Average Total Time (Days)	Average Research Office Time	Average Head of Dept Time	Average Chief Exec Time	Average Researcher Time
ASNSW	0	0	-	-	-	-	-	-
Calvary	8	8	100%	12	3	3	1	5
CCLHD	7	6	86%	44	14	11	0	19
FWLHD	0	0	-	-	-	-	-	-
HNELHD	22	21	95%	27	4	8	7	8
ISLHD	18	14	78%	34	5	6	0	24
JHFMHN	3	2	67%	64	35	29	0	0
MLHD	6	3	50%	49	14	6	0	29
MNCLHD	6	6	100%	22	3	9	11	0
NBMLHD	5	5	100%	39	15	18	1	5
NNSWLHD	1	1	100%	54	54	0	0	0
NSLHD	33	28	85%	40	14	10	4	12
NSWHPTH	9	8	89%	46	17	10	4	15
SCHN	22	15	68%	54	18	16	1	18
SESLHD	35	27	77%	52	24	9	0	19
SLHD-CCD	23	23	100%	24	3	5	5	11
SLHD-RPA	43	36	84%	35	11	8	6	10
SNSWLHD	2	0	0%	103	28	36	3	38
SVHN	18	12	67%	64	8	18	3	35
SWSLHD	44	40	91%	34	8	9	0	17
WNSWLHD	8	6	75%	38	6	14	0	18
WSLHD	53	39	74%	46	6	12	1	27
TOTAL	366	301	82%	43	12	10	3	18

Table 7: The 60 calendar days benchmark for the authorisation of clinical trials (greater than low risk) during the reporting period.

NSW PHOs	SSA Approvals (Q1 2025) Clinical Trials							
	Total Number of Applications	60 Day Benchmark (without clock)			Total Time Breakdown (calendar days)			
		Count of < 60 Day Benchmark	% < 60 Day Total Time Benchmark	Average Total Time (Days)	Average Research Office Time	Average Head of Dept Time	Average Chief Exec Time	Average Researcher Time
ASNSW	0	0	-	-	-	-	-	-
CALVARY	6	6	100%	8	3	3	1	1
CCLHD	3	3	100%	34	19	14	0	1
FWLHD	0	0	-	-	-	-	-	-
HNELHD	11	11	100%	25	4	9	5	6
ISLHD	11	7	64%	47	6	7	0	35
JHFMHN	0	0	-	-	-	-	-	-
MLHD	2	0	0%	72	18	6	0	49
MNCLHD	5	5	100%	20	2	5	12	0
NBMLHD	4	4	100%	39	18	15	1	5
NNSWLHD	1	1	100%	54	54	0	0	0
NSLHD	16	15	94%	30	11	9	4	5
NSWHPH	1	1	1	40	30	4	2	4
SCHN	10	7	70%	45	17	14	0	15
SESLHD	12	9	75%	53	25	15	1	13
SLHD-CCD	12	12	100%	26	4	5	7	10
SLHD-RPA	15	11	73%	39	11	11	6	12
SNSWLHD	1	0	0%	94	29	59	2	4
SVHN	10	7	70%	69	9	24	3	33
SWSLHD	22	19	86%	32	6	11	0	15
WNSWLHD	3	1	33%	49	7	27	0	15
WSLHD	34	28	82%	34	5	14	2	14
TOTAL	179	148	83%	41	12	12	3	15

Table 8. NSW PHO performances in clinical trial authorisations (greater than low risk) during the reporting period, by sponsor type.

	Collaborative group			Commercial entity			Investigator-initiated		
NSW PHOs	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)
ASNSW	0	-	-	0	-	-	0	-	-
CALVARY	0	-	-	6	3	8	0	-	-
CCLHD	0	-	-	1	14	37	2	21	33
FWLHD	0	-	-	0	-	-	0	-	-
HNELHD	5	3	34	2	5	9	4	5	21
ISLHD	3	3	74	8	7	37	0	-	-
JHFMHN	0	-	-	0	-	-	0	-	-
MLHD	0	-	-	0	-	-	2	18	72
MNCLHD	2	2	25	3	3	16	0	-	-
NBMLHD	1	12	28	3	20	42	0	-	-
NNSWLHD	0	-	-	1	54	54	0	-	-
NSLHD	1	11	14	12	11	28	3	14	41
NSWHPH	0	-	-	0	-	-	0	-	-
SCHN	1	26	36	4	5	34	5	24	57
SESLHD	3	38	55	3	35	56	6	12	51
SLHD-CCD	4	2	22	5	6	22	3	3	38
SLHD-RPA	2	12	54	9	14	39	4	4	33
SNSWLHD	0	-	-	0	-	-	1	29	94
SVHN	0	-	-	8	7	34	2	20	207
SWSLHD	8	6	28	12	7	29	2	6	69
WNSWLHD	0	-	-	1	3	20	2	9	64
WSLHD	3	11	101	22	3	24	9	9	37
Total	33	9	43	100	10	31	45	17	61

Table 9. Quarterly clinical trial authorisations (greater than low risk applications) approved during the last 3 reporting period, by sponsor type

	Q3 2024			Q4 2024			Q1 2025		
Sponsor Type	Total # of Applications	Average Research Office	Average Total Time	Total # of Applications	Average Research Office	Average Total Time	Total # of Applications	Average Research Office	Average Total Time
Collaborative Group	55	18	56	63	13	39	33	9	43
Commercial Entity	145	9	26	155	9	27	100	10	31
Investigator Initiated	64	15	74	53	18	59	45	17	61
Total	264	14	52	271	13	42	178	12	47

Table 10. Historical performance of NSW PHOs against the old and new benchmarks for the review and authorisation of SSA applications (greater than low risk) for the last 3 reporting periods (between 01/07/2024 and 31/03/2024).

	Q3 2024							Q4 2024							Q1 2025						
LHD	Number of Applications	15 Day Benchmark (with clock)			60 Day Benchmark (without clock)			Number of Applications	15 Day Benchmark (without clock)			60 Day Benchmark (without clock)			Number of Applications	15 Day Benchmark (with clock)			60 Day Benchmark (without clock)		
		Count of 15 Day Benchmark	% 15 Day Benchmark	Average RO Time (Days)	Count of 60 Day Benchmark	% 60 Day Total Time Benchmark	Average Total Time (Days)		Count of 15 Day Benchmark	% 15 Day Benchmark	Average RO Time (Days)	Count of 60 Day Benchmark	% 60 Day Total Time Benchmark	Average Total Time (Days)		Count of 15 Day Benchmark	% 15 Day Benchmark	Average RO Time (Days)	Count of 60 Day Benchmark	% 60 Day Total Time Benchmark	Average Total Time (Days)
ASNSW	1	0	0	16	1	100%	28	1	1	1	0	1	100%	12	0	0	-	-	0	-	-
CALVARY	22	12	55%	18	20	91%	27	15	14	93%	12	14	93%	16	8	8	100%	3	8	100%	12
CCLHD	7	5	71%	10	7	100%	19	12	10	83%	7	11	92%	16	7	5	71%	14	6	86%	44
FWLHD	0	0	-	-	0	-	-	0	0	-	-	0	-	-	0	0	-	-	0	-	-
HNELHD	39	37	95%	4	38	97%	24	37	32	86%	6	37	100%	23	22	20	91%	4	21	95%	27
ISLHD	13	11	85%	7	12	92%	32	12	11	92%	5	12	100%	20	18	17	94%	5	14	78%	34
JHFMHN	2	2	100%	7	2	100%	17	0	0	-	-	0	-	-	3	0	0	35	2	67%	64
MLHD	4	1	25%	20	3	75%	40	1	0	0%	25	1	100%	26	6	2	33%	14	3	50%	49
MNCLHD	6	3	50%	13	5	83%	37	9	7	78%	10	9	100%	30	6	6	100%	3	6	100%	22
NBMLHD	10	5	50%	23	9	90%	54	14	1	7%	30	13	93%	55	5	3	60%	15	5	100%	39
NNSWLHD	1	1	100%	0	1	100%	46	3	1	33%	18	3	100%	20	1	0	0%	54	1	100%	54
NSLHD	58	51	88%	7	52	90%	31	49	35	71%	11	47	96%	36	33	22	67%	14	28	85%	40
NSWHPH	13	6	46%	25	6	46%	92	16	6	38%	19	16	100%	41	9	5	56%	17	8	89%	46
SCHN	34	10	29%	25	15	44%	84	28	14	50%	18	19	68%	51	22	11	50%	18	15	68%	54
SESLHD	40	24	60%	15	40	100%	41	46	20	43%	17	43	93%	38	35	21	60%	24	27	77%	52
SLHD-CCD	26	25	96%	7	24	92%	37	38	37	97%	2	36	95%	31	23	21	91%	3	23	100%	24
SLHD-RPA	62	54	87%	6	54	87%	29	76	72	95%	7	65	86%	34	43	33	77%	11	36	84%	35
SNSWLHD	1	1	100%	0	1	100%	8	2	1	50%	50	1	50%	69	2	0	0%	28	0	0%	103
SVHN	23	18	78%	10	18	78%	54	30	21	70%	10	18	60%	64	18	15	83%	8	12	67%	64
SWSLHD	71	44	62%	24	39	55%	86	53	36	68%	13	49	92%	39	44	37	84%	8	40	91%	34
WNSWLHD	4	4	100%	13	4	100%	38	8	3	38%	31	5	63%	88	8	8	100%	6	6	75%	38
WSLHD	68	66	97%	5	57	84%	41	68	66	97%	8	57	84%	36	53	48	91%	6	39	74%	46
Total	505	380	75%	12	409	81%	47	518	388	75%	12	458	88%	38	366	282	77%	12	301	82%	43

A list of NSW PHOs names and abbreviations that review and/or authorise human research studies:

Human Research Ethics Committee/ Research Governance Office Names	Abbreviation used in the tables	Ethics	Site
Ambulance Service of NSW	ASNSW		Yes
Bellberry	BLLBRRY	Yes	
Calvary Mater Hospital Newcastle	CALVARY		Yes
Central Coast LHD	CCLHD		Yes
NSW Population & Health Services Research Ethics Committee	CINSW	Yes	
Greater Western LHD	WNSWLHD	Yes	Yes
Hammond Care	HCARE		Yes
Hunter New England LHD	HNELHD	Yes	Yes
Justice Health & Forensic Mental Health Network	JHFMHN	Yes	Yes
Mid North Coast LHD	MNCLHD		Yes
Murrumbidgee LHD	MLHD		Yes
Northern NSW LHD	NNSWLHD	Yes	Yes
Nepean Blue Mountains LHD	NBMLHD	Yes	Yes
Northern Sydney LHD	NSLHD	Yes	Yes
NSW Health Pathology	NSWHPTH		Yes
Royal Rehabilitation Centre Sydney HREC	RRCS	Yes	
Sydney Children's Hospitals Network	SCHN	Yes	Yes
South Eastern Sydney LHD	SESLHD	Yes	Yes
Sydney LHD (Concord Zone)	SLHD – CCD	Yes	Yes
Sydney LHD (RPAH Zone)	SLHD – RPA	Yes	Yes
Southern NSW LHD	SNSWLHD		Yes
St Vincent's Hospital	SVHN	Yes	Yes
South Western Sydney LHD	SWSLHD	Yes	Yes
Illawarra Shoalhaven LHD (joint committee with University of Wollongong)	ISLHD	Yes	Yes
Western Sydney LHD	WSLHD	Yes	Yes



For more information

This report has been prepared by the Research Ethics and Governance Unit in Office for Health and Medical Research.

For further enquiries and for the use of this report please contact:

James Cokayne

Principal Policy Officer

Research Ethics and Governance Unit

Office for Health and Medical Research

[Tel \(02\) 9391 9920](tel:0293919920) | james.cokayne@health.nsw.gov.au

Yagiz Aksoy

Senior Policy Officer

Research Ethics and Governance Unit

Office for Health and Medical Research

[Tel \(02\) 9461 7887](tel:0294617887) | yagiz.aksoy@health.nsw.gov.au

Deb Aldridge

Policy Officer and Data Analyst

Research Ethics and Governance Unit

Office for Health and Medical Research

[Tel \(02\) 93919854](tel:0293919854) | deborah.aldridge@health.nsw.gov.au